Overview
- Boston Scientific will purchase the remaining equity of Nalu Medical for about $533 million in cash, valuing the transaction at roughly $600 million on a full-equity basis.
- The acquisition broadens Boston Scientific’s chronic pain portfolio by adding peripheral nerve stimulation that complements its spinal cord stimulation and ablative pain therapies.
- Nalu’s FDA-cleared system delivers mild electrical impulses via a miniaturized, battery-free implant powered wirelessly by an external therapy disc and controlled through a smartphone app.
- Nalu is projected to generate more than $60 million in revenue in 2025 with growth above 25% in 2026, with adjusted earnings effects expected to be neutral in 2026 and modestly accretive in 2027.
- Closing is planned for the first half of 2026 pending customary approvals, and Boston Scientific shares rose about 1% following the announcement.